Clinical Trials Finder

My Profile

Update your profile and manage your search and notification preferences

Country*
Choose country*
Sex*
Age*
Your treatment status
Select...
Mobility
Select...

My search preferences

Preferred Study Status
All
Preferred Study Type
All

My notifications

Back to Map
RECRUITING
Updated: Nov 28, 2025

Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders

Phase
N/A
Early 1
1
2
3
4

Brief Summary

Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.

Key Information

Inclusion Criteria:

- Diagnosis with Cerebral palsy (CP), Duchenne muscular dystrophy (DMD) or Spinal muscular atrophy (SMA) resulting in the need of a wheelchair

Exclusion Criteria:

  • Use of anti-resorptive medication
  • Confounding illnesses
  • Pregnancy
  • Allergy towards the components given on the test days
  • Hgb<6.5 mmol/L

Newsletter sign up

Keep up-to-date with our news, actions and events. Sign up to receive our digital newsletter.

Contact SMA Europe

Subscribe to SMA Europe Newsletter